Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.

NCT03235687 is registered in ClinicalTrials.gov with Exosome Diagnostics, Inc. as lead sponsor.

NCT NCT03235687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03235687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.
Lead sponsor
Exosome Diagnostics, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
July 19, 2017
Completion date
September 29, 2023
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate